HC Wainwright Has Bearish Forecast for IPA FY2028 Earnings

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) – Investment analysts at HC Wainwright reduced their FY2028 earnings per share (EPS) estimates for ImmunoPrecise Antibodies in a note issued to investors on Monday, March 31st. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn $0.08 per share for the year, down from their previous forecast of $0.13. HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for ImmunoPrecise Antibodies’ current full-year earnings is ($0.27) per share. HC Wainwright also issued estimates for ImmunoPrecise Antibodies’ FY2029 earnings at $0.17 EPS.

ImmunoPrecise Antibodies (NASDAQ:IPA) last released its quarterly earnings results on Friday, March 28th. The company reported ($0.06) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.06). ImmunoPrecise Antibodies had a negative net margin of 114.50% and a negative return on equity of 73.74%. The company had revenue of $4.23 million for the quarter, compared to analyst estimates of $6.59 million.

Separately, Benchmark reissued a “speculative buy” rating and issued a $3.00 price target on shares of ImmunoPrecise Antibodies in a report on Tuesday.

ImmunoPrecise Antibodies Price Performance

Shares of NASDAQ IPA opened at $0.38 on Wednesday. The stock’s 50 day moving average price is $0.43 and its 200-day moving average price is $0.47. The company has a market capitalization of $11.78 million, a PE ratio of -0.49 and a beta of 0.09. ImmunoPrecise Antibodies has a twelve month low of $0.27 and a twelve month high of $1.50. The company has a quick ratio of 0.85, a current ratio of 1.01 and a debt-to-equity ratio of 0.36.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in ImmunoPrecise Antibodies stock. Ingalls & Snyder LLC boosted its holdings in shares of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) by 20.3% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,558,892 shares of the company’s stock after buying an additional 263,451 shares during the period. Ingalls & Snyder LLC owned approximately 5.41% of ImmunoPrecise Antibodies worth $996,000 as of its most recent SEC filing. 6.70% of the stock is owned by institutional investors.

About ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.